<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377869</url>
  </required_header>
  <id_info>
    <org_study_id>0018-14-BNZ</org_study_id>
    <nct_id>NCT02377869</nct_id>
  </id_info>
  <brief_title>Heavy Light Chain in Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Heavy Light Chain in Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laniado Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western Galilee Hospital-Nahariya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which&#xD;
      enables improvement in paraprotein detection and monitoring in multiple myeloma and other&#xD;
      plasma-cell dyscrasias.&#xD;
&#xD;
      The prognostic and biological role of the HLC assay has as yet not been studied in CLL.&#xD;
&#xD;
      Aims of the proposed study:&#xD;
&#xD;
        1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL&#xD;
           patients. (In addition to FLC)&#xD;
&#xD;
        2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of&#xD;
           patients with CLL and compare them to those of to healthy volunteers.&#xD;
&#xD;
        3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and&#xD;
           ITP)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of immunoglobulin heavy/light chain pairs In chronic lymphocytic leukemia&#xD;
&#xD;
      Introduction and Background:&#xD;
&#xD;
      Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the western world.&#xD;
      Median age at diagnosis is 72 years, and the male to female ratio is 2:1. The disease is&#xD;
      characterized by an accumulation of monoclonal mature B-cells which co-express the T-cell&#xD;
      antigen CD5, B-cell surface antigens CD19, CD20, and CD23(1) and either kappa or lambda&#xD;
      immunoglobulin light chains restriction (2). Diagnosis is established based on the IWCLL&#xD;
      criteria published by Hallek at al in 2008. (1).&#xD;
&#xD;
      CLL may have a heterogeneous clinical course with a wide spectrum of manifestations ranging&#xD;
      from long lived asymptomatic patients who never require treatment to those with a more rapid&#xD;
      clinical course and symptomatic progression. One of the remaining important challenges in CLL&#xD;
      is to stratify patients into different prognostic categories, so as to plan appropriate&#xD;
      targeted therapy when necessary . The most important prognostic factor in CLL relates to the&#xD;
      presence of typical genomic aberrations in the leukemic cell (3). Other essential prognostic&#xD;
      parameters include: CD38 expression, the presence of ZAP-70, immunoglobulin heavy chain&#xD;
      mutational status, and beta 2 microglobulin (B2MG) levels. (1).&#xD;
&#xD;
      Patients with CLL, have a 10 % risk of developing autoimmune complications mostly auto-immune&#xD;
      hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) (4-6). The pathogenesis for these&#xD;
      autoimmune cytopenias is linked to the production of polyclonal immunoglobulin G (IgG)&#xD;
      antibodies (less frequently IgM) directed against a variety of red blood cell or platelet&#xD;
      antigens. (4-6).&#xD;
&#xD;
      The use of serum free light chain (FLC) levels as an important prognostic tool in different&#xD;
      plasma cell dyscrasias is already well established (75) while the prognostic significance of&#xD;
      FLC in CLL has only been reported more recently by few publications (8-10). Furthermore, Tsai&#xD;
      et al, have also described that serum FLC abnormalities may precede diagnosis in 38 % of&#xD;
      patients with CLL (11).&#xD;
&#xD;
      Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which&#xD;
      enables improvement in paraprotein detection and monitoring in multiple myeloma and other&#xD;
      plasma-cell dyscrasias. (12-13).&#xD;
&#xD;
      The prognostic and biological role of the HLC assay has as yet not been studied in CLL.&#xD;
&#xD;
      Aims of the proposed study:&#xD;
&#xD;
        1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL&#xD;
           patients. (In addition to FLC)&#xD;
&#xD;
        2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of&#xD;
           patients with CLL and compare them to those of to healthy volunteers.&#xD;
&#xD;
        3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and&#xD;
           ITP)&#xD;
&#xD;
      Materials and methods:&#xD;
&#xD;
      The study will be performed in collaboration with the Israeli CLL Study Group.&#xD;
&#xD;
      All patients included will have complete clinical database available and medical records&#xD;
      summarized.&#xD;
&#xD;
      Baseline laboratory parameters to be examined will include: complete blood count, Coombs&#xD;
      test, serum B2MG and LDH, Immunoglobulin levels,, flow-cytometry including CD38 expression&#xD;
      and ZAP70 and urine Bence Jones protein.&#xD;
&#xD;
      Frozen serum samples from CLL patients will be analyzed for levels of:&#xD;
&#xD;
        -  Free light chain: kappa/lambda, ratio of K/L and total sum of K+L.&#xD;
&#xD;
        -  IgG1, IgG2, IgG3, IgG4.&#xD;
&#xD;
        -  Isoforms of heavy/light chain of IgG kappa, IgG lambda, IgA kappa, IgA lambda, IgM&#xD;
           kappa, IgM lambda&#xD;
&#xD;
      References:&#xD;
&#xD;
        1. Michael Hallek, Bruce D. Cheson, Daniel Catovsky, et al. Guidelines for the diagnosis&#xD;
           and treatment of chronic lymphocytic leukemia: a report from the International Workshop&#xD;
           on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group&#xD;
           1996 guidelines. Blood. Jun 15, 2008; 111(12): 5446-5456.&#xD;
&#xD;
        2. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia&#xD;
           scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin&#xD;
           Pathol.1997;108:378-382.&#xD;
&#xD;
        3. DÃ¶hner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic&#xD;
           lymphocytic leukemia. N Engl J Med. 2000 Dec 28; 343(26):1910-6.&#xD;
&#xD;
        4. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin&#xD;
           Pathol 1986;39;713-16&#xD;
&#xD;
        5. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best&#xD;
           Pract Res Clin Haematol. 2010 Mar;23(1):47-59.&#xD;
&#xD;
        6. Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune&#xD;
           cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014 Jun 10&#xD;
&#xD;
        7. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines&#xD;
           for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia.&#xD;
           2009 Feb;23(2):215-24.&#xD;
&#xD;
        8. Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light&#xD;
           chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011 Sep&#xD;
           8;118(10):2821-6&#xD;
&#xD;
        9. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light&#xD;
           chain is a strong prognosticator in chronic lymphocytic leukemia. Blood. 2011 Dec&#xD;
           8;118(24):6353-61.&#xD;
&#xD;
       10. Sarris K, Maltezas D, Koulieris E, et al. Prognostic significance of serum free light&#xD;
           chains in chronic lymphocytic leukemia. Adv Hematol. 2013;2013:359071&#xD;
&#xD;
       11. Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up&#xD;
           to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.&#xD;
           Blood. 2009 Dec 3;114(24):4928-32&#xD;
&#xD;
       12. Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios&#xD;
           improve paraprotein detection and monitoring, identify residual disease and correlate&#xD;
           with survival in multiple myeloma patients. Leukemia. 2013 Apr;27(4):996.&#xD;
&#xD;
       13. Katzmann JA, Clark R, Kyle RA, et al. Suppression of uninvolved immunoglobulins defined&#xD;
           by heavy/light chain pair suppression is a risk factor for progression of MGUS.&#xD;
           Leukemia. 2013 Jan;27(1):208-12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1) To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>CLL</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervantion</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Age&gt;18 years Patients diagnosed with CLL&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        New diagnosed patients with CLL (untreated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Not treated with immunoglobulin Not treated with steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Tadmor, MD</last_name>
      <phone>+97248359</phone>
      <phone_ext>407</phone_ext>
      <email>tamar.tadmor@b-zion.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bnai Zion Medical Center</investigator_affiliation>
    <investigator_full_name>tamar.tadmor</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

